Navigation Links
Yuma Therapeutics Awarded a Research Grant by the Alzheimer's Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimer's Disease
Date:3/28/2011

NEW YORK, March 28, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $249,810 to Yuma Therapeutics Corporation (Yuma) to develop small molecules to treat Alzheimer's disease.

(Logo: https://photos.prnewswire.com/prnh/20090805/DC57332LOGO)

The award will fund work to develop Yuma's innovative disease-modifying pharmaceutical compounds that target neurofibrillary tangles resulting from abnormal forms of the protein tau, which represents a promising new approach with potential to affect disease progression in Alzheimer's disease.

"We are excited to support Yuma Therapeutics innovative program in this area," said Howard Fillit, M.D., executive director of the ADDF.  "Small molecule therapeutics targeting the tau pathway could result in a disease-modifying therapy for Alzheimer's disease."

"We are honored to be selected for this peer-reviewed grant, which recognizes the promise of Yuma's approach to generating novel Alzheimer's disease therapies," said Yukari Y. Perrella, founder and president of Yuma.  "We look forward to interacting with the ADDF team."

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)

The ADDF is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery and development programs in academic centers and biotechnology companies in 17 countries. 

About Yuma Therapeutics Corporation (www.yumatherapeutics.com)

Yuma Therapeutics is a privately held biopharmaceutical company focused on developing novel disease-modifying small molecule drugs to treat neurodegenerative diseases.  The Company is developing pharmaceutical compounds that target the tau pathway, a promising new approach to affect the disease progression of Alzheimer's disease.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
2. Reportlinker Adds Therapeutics for Immune System Disorders
3. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
4. Echo Therapeutics Hires Two Seasoned Medical Device and Diagnostics Executives
5. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
6. Echo Therapeutics Announces 2010 Financial Results
7. Nile Therapeutics Reports 2010 Fourth Quarter and Full Year Financial Results
8. Reportlinker Adds Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
10. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
11. PNP Therapeutics Meets Important Financial and Regulatory Objectives in Development of New Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
Breaking Medicine News(10 mins):